For many dealing with chronic and painful conditions like eczema or nasal polyps, finding the right medication that brings relief feels like a miracle. When Dupixent (dupilumab) became available, it offered real hope for patients who had long struggled to find something that actually worked.
This injectable drug has offered a new sense of comfort to countless individuals. However, for some, the relief has been tragically overshadowed by a devastating diagnosis: T-cell lymphoma, a serious form of cancer.
At Freese & Goss, we understand how devastating a cancer diagnosis can be, especially when it may be connected to a drug you trusted. The idea of taking legal action might feel out of reach right now, but we take pride in making the legal process as clear and manageable as possible.
With over $1 billion in settlements and verdicts and 77 years of combined experience, we’ve helped people just like you hold powerful companies accountable.
If you believe your T-cell lymphoma diagnosis may be linked to Dupixent, reach out today online or by calling 214-761-6623. Your consultation is free, confidential, and comes with zero obligation.
“They handled everything professionally, and even in a hard spot, they were able to help me. This is your winning team; they won’t let you down.”
Daniel U. | Client
What Is Dupixent?
Dupixent, also known by its generic name dupilumab, is a biologic drug that hit the market in 2017. Biologic drugs are types of medication made from living organisms. Unlike traditional drugs that work on the whole body, biologics are designed to target specific parts of the immune system.
Dupixent works by blocking two proteins, IL-4 and IL-13, that are involved in the inflammation that causes the symptoms of:
- Moderate-to-severe eczema (atopic dermatitis)
- Asthma
- Chronic sinusitis with nasal polyps
- Eosinophilic esophagitis
While many people experience significant relief from their symptoms, the drug is not without side effects. The manufacturers of Dupixent, Sanofi and Regeneron, did warn patients of effects, such as:
- Injection site reactions
- Eye problems (such as conjunctivitis)
- Oral herpes
However, what patients and doctors were not warned about was the potential for a serious, life-threatening risk of the development or worsening of T-cell lymphoma.
Why Are People Filing a Dupixent Lawsuit?
When a pharmaceutical company fails to warn the public about a dangerous side effect, it can be held legally responsible for the harm it causes. Studies published in 2024 and 2025 show that people taking Dupixent may face a 300% higher risk of developing cutaneous T-cell lymphoma (CTCL), a rare but aggressive form of non-Hodgkin lymphoma.
Despite this alarming risk, the drug’s manufacturers, Sanofi and Regeneron, did not warn doctors or patients. This failure to disclose a potentially life-threatening side effect has left many families blindsided by a devastating cancer diagnosis.
The lawsuits against Sanofi and Regeneron are based on several serious claims:
- Sanofi and Regeneron marketed Dupixent without properly warning patients or healthcare providers about the risk of developing cutaneous T-cell lymphoma.
- CTCL often presents with symptoms that resemble eczema, the very condition Dupixent is prescribed to treat. Without proper warnings, patients and doctors were unable to distinguish between typical eczema flares and signs of something much more serious, delaying diagnosis and treatment.
- Lawsuits claim the manufacturers either knew, or should have known, about the connection between Dupixent and T-cell lymphoma during clinical trials or after the drug entered the market.
When early signs of T-cell lymphoma are mistaken for eczema, precious time is lost. What could have been caught and treated earlier may instead progress into something far more serious. For many patients, the realization comes too late.
At Freese & Goss, we are committed to uncovering the truth and holding drug manufacturers accountable for their failure to warn. Contact us today for a free, confidential case review online or by calling 214-761-6623.
Research Behind Dupixent and Cancer Claims
Several well-respected studies published in 2024 and 2025 have found a significantly increased risk of T-cell lymphoma in patients treated with Dupixent, particularly those with eczema and asthma.
Here’s what the research shows:
Study April 2024
This study looked at whether people with eczema who were treated with Dupixent had a higher risk of developing CTCL than those who didn’t take the drug.
- In the first analysis, Dupixent users were over 4 times more likely to develop CTCL.
- Even after accounting for factors like sex, race, and other medications, the risk remained more than double.
- The researchers concluded that Dupixent may significantly raise the risk of this rare cancer in certain patients.
Study August 2024
A second study using TriNetX health data further supported these findings.
- Patients with eczema who were treated with Dupixent had a 350% higher risk of developing CTCL compared to matched patients who did not take the drug.
- This study excluded patients with other inflammatory conditions or those using other biologics that might have skewed the results, strengthening the link between Dupixent and CTCL.
Study June 2025
In this more recent study, researchers focused on asthma patients, not eczema, and still found disturbing results.
- Compared to patients using traditional asthma therapies (ICS/LABA), those treated with Dupixent had a 4.5 times greater risk of developing CTCL.
- Dupixent was also associated with an overall higher risk of all lymphomas, not just CTCL.
- In patients who had been on Dupixent for at least 16 weeks, the risk skyrocketed, especially for a broader group of blood cancers known as mature T and NK cell lymphomas, which showed a 14-fold increase in risk.
Dupixent works by changing how your immune system responds. While that can reduce inflammation and help manage chronic conditions, it may also affect how the body detects and controls abnormal or cancerous cells.
In short, some researchers believe Dupixent could allow certain lymphomas, like CTCL, to develop faster, or stay hidden longer, especially in patients already at risk.
While past results don’t guarantee future outcomes, they reflect that having a lawyer on your side can help you feel more confident in taking on a lawsuit and may improve your chances of recovering meaningful compensation. For example, in a nationwide Martindale-Nolo study, over 90% of people who hired a personal injury lawyer received compensation, compared to just 51% of those who handled their claims on their own.
At Freese & Goss, we’re not new to these kinds of battles over defective drugs and medical devices. Our firm helped secure a $33.6 million verdict in a case involving a defective IVC filter and a $3 million verdict in a lawsuit over the failure to warn about birth defect risks linked to the drug Topamax.
Do I Qualify for a Dupixent Lymphoma Lawsuit?
If you or a loved one used Dupixent and were later diagnosed with T-cell lymphoma, you may be entitled to significant compensation. You may qualify for a Dupixent lawsuit if:
- You were administered Dupixent by injection.
- You received injections for at least 30 days.
- Your last injection occurred between 2017 and the present.
- You were diagnosed with T-cell lymphoma, especially CTCL (cutaneous T-cell lymphoma).
Even if you’re not sure you meet all of these criteria, we encourage you to contact us online or by calling 214-761-6623. Our Dupixent lawsuit lawyers will be able to review the specifics of your situation to determine your eligibility.
Why Work With the Dupixent Lawsuit Attorneys at Freese & Goss?
Learning you have T-cell lymphoma is devastating. But finding out it may have been caused, or made worse, by a drug you trusted to help you feel better? That is more than just a medical crisis. You should have been warned. You should have had the chance to make informed choices. You deserved the truth.
At Freese & Goss, we understand you’re not just dealing with a legal issue. You’re facing a frightening diagnosis, expensive medical bills, and a future that now looks very different from what you expected.
We are not just another law firm hoping for a quick settlement. We are a nationally recognized trial firm with more than $1 billion recovered for clients and 77 years of combined experience in personal injury and mass tort litigation. Our team has been chosen for leadership roles in major national lawsuits because we build strong cases and deliver real results.
If you or someone you love developed cutaneous T-cell lymphoma (CTCL) after using Dupixent, you may be eligible for financial compensation in a Dupixent class action lawsuit. Reach out to Freese & Goss today for a 100% free case review online or by calling 214-761-6623.
Dupixent Lawsuit FAQs
What Kind of Compensation Is Available in a Dupixent Lymphoma Lawsuit?
If your lawsuit is successful, you may be able to recover compensation for the harm Dupixent has caused. This can include medical bills, both past and ongoing, lost income from time away from work, and the pain, suffering, and emotional toll that comes with a serious illness like T-cell lymphoma.
If you’re pursuing a claim on behalf of a loved one who passed away, your family may also be entitled to damages for funeral expenses, loss of companionship, and other related losses.
How Much Does It Cost to Hire the Dupixent Lawsuit Lawyers at Freese & Goss?
We know that after a serious diagnosis, the last thing you want to worry about is how to afford a lawyer. That’s why we handle Dupixent cases on a contingency fee basis. You pay nothing up front, and there are no out-of-pocket costs to get started. We cover all the expenses of building your case. You only pay us if we win, either through a settlement or a verdict in your favor.
If there’s no recovery, you owe us nothing.
How Do I Prove My T-Cell Lymphoma Is Related to My Dupixent Use?
Establishing a connection between your diagnosis and Dupixent use involves a careful review of your medical records, treatment timeline, and symptoms. This is where having an experienced legal team can make a real difference.
At Freese & Goss, we work with trusted medical experts who can analyze your case and help determine whether there is a likely link. We gather the right records, consult with specialists, and build a case that is backed by evidence.
What Symptoms Should I Watch for If I or a Loved One Is Using Dupixent?
If skin symptoms are not getting better with Dupixent, or if the rash starts to look different, becomes more widespread, or gets worse over time, that may be a reason for concern. Some patients have reported persistent itching, the appearance of new lumps or patches, swollen lymph nodes, or unexplained weight loss.
These signs can sometimes be confused with eczema flares, which is why it is important to pay close attention to changes. If symptoms are not improving, ask your doctor about further testing. A skin biopsy or specialist referral may help rule out or confirm something more serious, like cutaneous T-cell lymphoma.
